STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Evogene SEC Filings

EVGN Nasdaq

Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Evogene’s multi-subsidiary disclosures can feel overwhelming; a single 10-K packs gene-editing breakthroughs, microbiome trial results, and castor-seed revenue into more than 300 pages. That’s why Stock Titan offers Evogene SEC filings explained simply. Whether you need the science behind MicroBoost AI or the cash burn of Biomica, our AI highlights the essentials and drops you at the exact section—no manual scrolling.

Ask natural questions like “Where can I find the Evogene quarterly earnings report 10-Q filing?” or “Track Evogene insider trading Form 4 transactions.” Our platform answers in plain English and links directly to each document. Real-time feeds push Evogene Form 4 insider transactions real-time to your dashboard, while instant cards titled “Evogene 8-K material events explained” flag every development. Built-in analytics surface R&D spend shifts and segment margins, turning raw text into insight faster than you can open EDGAR.

For deeper research, dive into the Evogene annual report 10-K simplified to uncover revenue by tech-engine, or open the Evogene proxy statement executive compensation to review option grants and board pay. AI-curated dashboards show Evogene executive stock transactions Form 4 alongside price performance, giving context to buying or selling. Whether you’re understanding Evogene SEC documents with AI or seeking Evogene earnings report filing analysis for your model, Stock Titan converts complex biotech filings into immediate clarity.

Rhea-AI Summary

Evogene Ltd. furnished its unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the six-month period ended June 30, 2025. The filing lists interactive data files for consolidated interim statements of financial position, profit or loss, changes in equity, cash flows and notes. Exhibits 99.1 and 99.2 are incorporated by reference into the company’s registration statements on Form F-3 and Form S-8 and will form part of those filings to the extent not later superseded. The Form 6-K is signed by the CFO and serves to furnish interim financial reporting and management commentary for the first half of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Evogene (EVGN)?

The current stock price of Evogene (EVGN) is $1.24 as of November 11, 2025.

What is the market cap of Evogene (EVGN)?

The market cap of Evogene (EVGN) is approximately 10.3M.
Evogene

Nasdaq:EVGN

EVGN Rankings

EVGN Stock Data

10.33M
8.63M
0.96%
1.61%
1.23%
Biotechnology
Healthcare
Link
Israel
Rehovot